secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001193125-26-168287
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna reports positive miv-cel Phase 2 data in gMG and registrational SPS trial
--------------------------------------------------------------------------------

- KYSA-6 Phase 2/3 trial of miv-cel in generalized myasthenia gravis: positive longer-term follow-up from Phase 2 portion.
- KYSA-8 registrational trial of miv-cel in stiff person syndrome achieved positive primary analysis results.
- Conference call held April 22, 2026 to review both data sets; slides furnished as Exhibit 99.1.
- Data presented at AAN 2026 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526168287/0001193125-26-168287-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312526168287/d100817d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-168287

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer